#OP0209 #EULAR2026 SPECIFI-RA

      Balinatunfib, oral selective TNFR1 inhibitor designed to preserve TNFR2 signalling in RA.

      Mrinalini Dey DrMiniDey

      5 days 12 hours ago
      #OP0209 #EULAR2026 SPECIFI-RA Balinatunfib, oral selective TNFR1 inhibitor designed to preserve TNFR2 signalling in RA. Phase 2b trial missed primary ACR20 endpoint, but 200mg QD arm showed signals for higher ACR50, ACR70 and DAS28 low disease activity & reduced IL-6. @RheumNow https://t.co/emxNQy0cPx
      #EULAR2026 Recommendations: Vasculitis

      -Confirm diagnosis with imaging and biopsy
      - Start GC early but with taper plan

      Jiha Lee JihaRheum

      5 days 13 hours ago
      #EULAR2026 Recommendations: Vasculitis -Confirm diagnosis with imaging and biopsy - Start GC early but with taper plan - For major flare again confirm dx and restart GC - Consider IL-6 or UPA - MTX may be option if biologics not available @RheumNow https://t.co/DqLZtW630y
      Emapalumab in MAS secondary to stills disease
      39 pts, median age 12, 2 pooled prospective, open label, single arm studie

      Bella Mehta bella_mehta

      6 days 7 hours ago
      Emapalumab in MAS secondary to stills disease 39 pts, median age 12, 2 pooled prospective, open label, single arm studies. Endpoint complete resolution at week 8-. Around 60% and partial resolution nearly 100% 67% had concomitant anakinra @RheumNow ##EULAR2026 #EULARBest https://t.co/sGm43C3LfH
      light bulb idea
      Three Abstracts That May Shape the Future of RA Treatment
      1 week ago
      Our therapeutic armamentarium in RA keeps on growing. New studies and new molecules, new mechanisms of action or new ways of using old drugs are presented every year at conferences. But which are the ones who can have an impact on our practice? Here is my selection of 3 abstracts presented at EULAR 2026 that identify therapeutic strategies that are well worth keeping on our radar.
      Window of opportunity in stills disease is early. With IL1 / IL6 agents
      #sJIA and #AOSD are the same disease. - may need

      Bella Mehta bella_mehta

      1 week ago
      Window of opportunity in stills disease is early. With IL1 / IL6 agents #sJIA and #AOSD are the same disease. - may need a standard new crieteria IL18 measuremnet should be encouraged. @RheumNow #EULAR2026 plenary https://t.co/EQbs9mDYjS
      What to use in #RA #IL6i v #abatacept post #TNFi-IR?
      H2H #TCZ v #Abatacept

      Same on primary outcome
      #CDAI change wk26
      BU

      Janet Pope Janetbirdope

      1 week ago
      What to use in #RA #IL6i v #abatacept post #TNFi-IR? H2H #TCZ v #Abatacept Same on primary outcome #CDAI change wk26 BUT If #monoRx TCZ better Better retention #TCZ So you decide which is better! Equal v some advantages w #tocilizumab #EULAR2026 @RheumNow @eular_org #OP0205 https://t.co/xdOx4kQCTC
      Is there a ‘window
      Of opportunity’ for Rx
      #GCA w #IL6i
      🤞
      Obtain a better response

      Rx GCA #GC
      #TCZ
      #Upadacitinib

      Janet Pope Janetbirdope

      1 week ago
      Is there a ‘window Of opportunity’ for Rx #GCA w #IL6i 🤞 Obtain a better response Rx GCA #GC #TCZ #Upadacitinib #MTX Study tries to answer if effects of #tocilizumab early vs >8wks is diff N=471, 19% new GCA Early vs late TCZ no dif ❎No Not RCT POS0624 #EULAR2026 @RheumNow
      safety data
      JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal
      1 week 1 day ago
      Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings.

      Catch up on Conference Podcasts

      ×